Literature DB >> 21906675

Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway.

Haitao Wang1, Qishan Zhang, Qiang Wen, Yongxin Zheng, Philip Lazarovici, Lazarovici Philip, Hao Jiang, Jun Lin, WenHua Zheng.   

Abstract

Modifications in signaling of the proline-rich Akt substrate of 40-kDa (PRAS40) pathway is implicated in type 2 diabetes and melanoma. PRAS40 is known for its ability to regulate the mammalian target of rapamycin complex 1 (mTORC1) kinase activity, possessing a key regulatory role at the cross point of signal transduction pathways activated by growth factor receptors. Recently it has been found that PRAS40 is regulated by its upstream phosphatidylinositol 3-kinase/Akt (PI3K/Akt) which is activated by many tyrosine kinase receptors growth factors including insulin-like growth factor 1. Also, PRAS40 functions downstream of mTORC1 and upstream from its effectors ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1). Phosphorylation of PRAS40 by Akt and mTORC1 disrupts the binding between mTORC1 and PRAS40, and relieves the inhibitory constraint of PRAS40 on mTORC1 activity. This review summarizes the signaling regulating PRAS40 phosphorylation, as well as the dual function of PRAS40 as substrate and inhibitor of mTORC1 upon growth factor stimulation and under pathophysiological conditions.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21906675     DOI: 10.1016/j.cellsig.2011.08.010

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  58 in total

1.  Calorie restriction leads to greater Akt2 activity and glucose uptake by insulin-stimulated skeletal muscle from old rats.

Authors:  Haiyan Wang; Edward B Arias; Gregory D Cartee
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-01-06       Impact factor: 3.619

Review 2.  Stem cell guidance through the mechanistic target of rapamycin.

Authors:  Kenneth Maiese
Journal:  World J Stem Cells       Date:  2015-08-26       Impact factor: 5.326

Review 3.  Programming apoptosis and autophagy with novel approaches for diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2015       Impact factor: 1.990

4.  Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling.

Authors:  Inchul You; Emily C Erickson; Katherine A Donovan; Nicholas A Eleuteri; Eric S Fischer; Nathanael S Gray; Alex Toker
Journal:  Cell Chem Biol       Date:  2019-12-16       Impact factor: 8.116

5.  A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Future Neurol       Date:  2012-11

6.  Wnt1 inducible signaling pathway protein 1 (WISP1) targets PRAS40 to govern β-amyloid apoptotic injury of microglia.

Authors:  Yan Chen Shang; Zhao Zhong Chong; Shaohui Wang; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2012-11       Impact factor: 1.990

7.  mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  World J Diabetes       Date:  2015-03-15

8.  Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

Authors:  Brittany Knick Ragon; Olatoyosi Odenike; Maria R Baer; Wendy Stock; Gautam Borthakur; Keyur Patel; Lina Han; Helen Chen; Helen Ma; Loren Joseph; Yang Zhao; Keith Baggerly; Marina Konopleva; Nitin Jain
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-03-26

9.  Mechanisms mediating the effects of alcohol and HIV anti-retroviral agents on mTORC1, mTORC2 and protein synthesis in myocytes.

Authors:  Ly Q Hong-Brown; Abid A Kazi; Charles H Lang
Journal:  World J Biol Chem       Date:  2012-06-26

10.  Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary.

Authors:  Takeshi Hisamatsu; Seiji Mabuchi; Yuri Matsumoto; Mahiru Kawano; Tomoyuki Sasano; Ryoko Takahashi; Kenjiro Sawada; Kimihiko Ito; Hirohisa Kurachi; Russell J Schilder; Joseph R Testa; Tadashi Kimura
Journal:  Mol Cancer Ther       Date:  2013-04-24       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.